Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 20/20 | 0.84 |
| ▸ | SLC6A2 | P23975 | 19/20 | 0.84 |
| ▸ | SLC6A3 | Q01959 | 12/20 | 0.84 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.82 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6994188 | 1.00 | SLC6A4 (0.84) | SLC6A4SLC6A2SLC6A3CYP2D6CYP1A2 | |
| SCHEMBL6990556 | 1.00 | SLC6A4 (0.84) | SLC6A4SLC6A2SLC6A3CYP2D6CYP1A2 | |
| Hydrochloric Acid SCHEMBL6996236 | 0.99 | SLC6A2 (0.82) | SLC6A4SLC6A2SLC6A3CYP2D6CYP1A2 | |
| Hydrochloric Acid SCHEMBL8568964 | 0.99 | SLC6A2 (0.82) | SLC6A4SLC6A2SLC6A3CYP2D6CYP1A2 | |
| SCHEMBL3466313 | 0.92 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL1981733 | 0.92 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL1981732 | 0.92 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL14415545 | 0.92 | SLC6A4 (0.71) | SLC6A4SLC6A2SLC6A3CYP2D6CYP1A2 | |
| SCHEMBL8458076 | 0.90 | SLC6A4 (1.00) | SLC6A4SLC6A2SLC6A3CYP2D6 | |
| SCHEMBL9027256 | 0.86 | SLC6A4 (0.80) | SLC6A4SLC6A2SLC6A3CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7271172-B2 | Pyrrolidine and azetidine compounds as CCR5 antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 2007-09-18 | — | — | US | disclosed |
| US-7271172-B2 | Pyrrolidine and azetidine compounds as CCR5 antagonists | SMITHKLINE BEECHAM CORPORATION (US) | 2007-09-18 | — | — | US | disclosed |
| EP-0920425-B1 | SUBSTITUTED 4-(1H-BENZIMIDAZOL-2-YL-AMINO)PIPERIDINES USEFUL FOR THE TREATMENT OF ALLERGIC DISEASES | AVENTIS PHARMA INC (US) | 2003-02-19 | — | — | EP | disclosed |
| EP-0848706-B1 | SUBSTITUTED BENZENE-FUSED HETEROCYCLICS AS NEUROKININ ANTAGONISTS | SCHERING CORP (US) | 2003-02-05 | — | — | EP | disclosed |
| CN-1098259-C | Novel carboxy-substituted cyclic carboxamide derivatives | AVENTIS PHARMA INC (US) | 2003-01-08 | — | — | CN | disclosed |
| EP-0874843-B1 | SUBSTITUTED 4-(1H-BENZIMIDAZOL-2-YL) 1,4]DIAZEPANES USEFUL FOR THE TREATMENT OF ALLERGIC DISEASES | AVENTIS PHARMA INC (US) | 2002-08-07 | — | — | EP | disclosed |
| US-6423704-B2 | CROHN'S DISEAS, ANTIULCER AGENTS, ASTHMA, EMESIS | AVENTIS PHARMACEUTICALS INC. | 2002-07-23 | — | — | US | disclosed |
| EP-0946548-B1 | NOVEL HETEROCYCLIC SUBSTITUTED PYRROLIDINE AMIDE DERIVATIVES | AVENTIS PHARMA INC (US) | 2002-03-06 | — | — | EP | disclosed |
| US-6329392-B1 | ANTIALLERGENS | AVENTIS PHARMACEUTICALS, INC. | 2001-12-11 | — | — | US | disclosed |
| US-20010034343-A1 | Novel substituted 4-(1H-benzimidazol-2-yl) [1,4]diazepanes useful for the treatment of allergic diseases | AVENTIS PHARMACEUTICALS INC. | 2001-10-25 | — | — | US | disclosed |
| US-5607947-A | Pyrrolidinyl tachykinin receptor antagonists | ELI LILLY AND COMPANY (US) | 1997-03-04 | — | — | US | disclosed |
| WO-1996039383-A1 | SUBSTITUTED BENZENE-FUSED HETERO- AND CARBOCYCLICS AS NEUROKININ ANTAGONISTS | SCHERING CORPORATION (US) | 1996-12-12 | — | — | WO | disclosed |
| US-5583134-A | QUATERNARY BASIC AMIDE DERIVATIVES; USEFUL FOR TREATING PATHOLOGICAL CONDITION INVOLVING THE TACHYKININ SYSTEM | SANOFI (FR) | 1996-12-10 | — | — | US | disclosed |
| US-5554763-A | TACHYKININ ANTAGONISTS | SANOFI (FR) | 1996-09-10 | — | — | US | disclosed |
| CN-1124961-A | Substituted pyrrolidin-3-Yl-alkyl-piperidines useful as tachykinin antagonists | MERRELL DOW PHARMA (US) | 1996-06-19 | — | — | CN | disclosed |
| EP-0714891-A1 | Heterocyclic tachykinin receptor antagonists | ELI LILLY AND COMPANY (US) | 1996-06-05 | — | — | EP | disclosed |
| WO-1996006094-A1 | NOVEL SUBSTITUTED PIPERIDINES USEFUL FOR THE TREATMENT OF ALLERGIC DISEASES | MERRELL PHARMACEUTICALS INC. (US) | 1996-02-29 | — | — | WO | disclosed |
| EP-0696280-A1 | SUBSTITUTED PYRROLIDIN-3-YL-ALKYL-PIPERIDINES USEFUL AS TACHYKININ ANTAGONISTS | MERRELL DOW PHARMA (US) | 1996-02-14 | — | — | EP | disclosed |
| WO-1994026735-A1 | SUBSTITUTED PYRROLIDIN-3-YL-ALKYL-PIPERIDINES USEFUL AS TACHYKININ ANTAGONISTS | MERRELL DOW PHARMACEUTICALS INC. (US) | 1994-11-24 | — | — | WO | disclosed |
| EP-0591040-A1 | Quaternary basic amides as tachykinines antagonists | SANOFI (FR) | 1994-04-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010034343-A1 | Novel substituted 4-(1H-benzimidazol-2-yl) [1,4]diazepanes useful for the treatment of allergic diseases | HRH4, HRH2, HRH1 | SLC6A4 1652/4885SLC6A2 3664/4885SLC6A3 3128/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.